Haystack Oncology has developed a highly sensitive minimal-residual disease (MRD) testing technology, based on circulating tumor DNA (ctDNA), to aid in the early detection of residual or recurring cancer and better inform therapy decisions.
Acquired back in April, the acquisition will leverage Quest’s expertise and scale in oncology, genomics and pathology. Quest expects to incorporate this MRD technology into the development of new blood-based clinical lab services for solid tumor cancers available beginning in 2024.
A convicted felon who hopscotched his way into high-paying health executive positions all over the country despite a federal prison term has once again landed
Scott Sirdevan, CEO of Vorro Despite government mandates and advancements in technology, EHR interoperability remains a significant challenge for clinicians. A recent KLAS report highlighted
Quest Diagnostics Completes Acquisition of Haystack Oncology
by Healthcare M&A Leave a Comment
What You Should Know:
‘Con Man’ Gets Another Top Hospital Job, This Time at Penn Medicine
A convicted felon who hopscotched his way into high-paying health executive positions all over the country despite a federal prison term has once again landed
‘Best Medical Schools’ Rankings Delayed for Second Year in a Row
For a second year in a row, the “Best Medical Schools” rankings from U.S. News & World Report have been delayed. This year’s rankings were
Vorro CEO Talks Bridging the Interoperability Gap in Healthcare
Scott Sirdevan, CEO of Vorro Despite government mandates and advancements in technology, EHR interoperability remains a significant challenge for clinicians. A recent KLAS report highlighted